Steven Gourlay

Steven Gourlay

Chief Executive Officer at ACTINOGEN MEDICAL LIMITED

Net worth: 5 M $ as of 2026-05-30

66 year
Health Technology
Consumer Services
Distribution Services

Profile

Dr. Steven G.
Gourlay
is a Chief Executive Officer, MD & Director at Actinogen Medical Ltd. He is on the Board of Directors at Actinogen Medical Ltd. Dr. Gourlay was previously employed as a Chief Medical Officer by Principia Biopharma, Inc., a Partner by GBS Venture Partners Pty Ltd., a Senior Director-Clinical & Safety by Genentech, Inc., a Faculty Member by Monash University, and a Non-Executive Director by Verva Pharmaceuticals Ltd. He also served on the board at Applied Physiology Pty Ltd., Elastagen Pty Ltd. and Endoluminal Sciences Pty Ltd. He received his undergraduate degree from the University of Melbourne, an MBA from Macquarie University, a doctorate degree from The University of California, San Francisco and a doctorate degree from Monash University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-05-12 165,275,557 ( 4.52% ) 5 M $ 2026-05-30

Steven Gourlay active positions

CompaniesPositionStart
ACTINOGEN MEDICAL LIMITED Chief Executive Officer 2021-03-14

Former positions of Steven Gourlay

CompaniesPositionEnd
PRINCIPIA BIOPHARMA INC. Chief Tech/Sci/R&D Officer 2018-10-23
Corporate Officer/Principal 2003-12-31
Director/Board Member -
Director/Board Member -
Director/Board Member -
See the detail of Steven Gourlay's experience

Training of Steven Gourlay

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

87

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Technology

Health Technology

Consumer Services

Consumer Services

Finance

Consumer Services

Consumer Services

Health Technology

Distribution Services

Health Technology

Health Technology

Distribution Services

  1. Stock Market
  2. Insiders
  3. Steven Gourlay
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!